Rhode Island Blood Center and New York Blood Center Join Forces
Partnership will create largest state-of-the-art infectious disease testing laboratory in the Northeastern United States, bringing jobs to RI while carrying out life-saving missions.
PROVIDENCE, RI AND NEW YORK, NY (July 11, 2017) – Rhode Island Blood Center (RIBC) and New York Blood Center (NYBC) announced today that they have entered into an affiliation agreement expanding one of the leading blood center networks in the United States.
The strengths of RIBC, which built a 20,000 square foot full-service state-of-the-art testing laboratory in 2013 -- the only one of its kind in New England -- combined with NYBC's breadth of transfusion-related medical services and renowned research institute will further the life-saving impact and outcomes of these organizations.
Lawrence F. Smith, President and CEO of RIBC, says, “Our partnership with New York Blood Center, who we have worked with for decades, allows us to grow and expand our laboratory services with potential to add new customers. We will initially add 15 new quality medical-technical jobs to our Providence location, while allowing us to expand into exciting new areas, such as translational and applied research that NYBC specializes in to help develop better treatments for all types of diseases." RIBC's laboratory services include testing and pathogen reduction of donated blood and blood products, human leukocyte antigen (HLA) histocompatibility and red cell typing, immunogenics, as well as DNA and relationship testing.
Christopher D. Hillyer, M.D., President and CEO of NYBC, said: “We’re extremely pleased to be partnering with such an excellent blood center. NYBC and RIBC have a remarkable alignment of mission, vision and talent. We look forward to working together to ensure the finest customer-focused service for our hospitals and patients.”
The NYBC network of blood centers is responsible for providing over 800,000 units of blood annually, of which RIBC is currently responsible for approximately 75,000 units.
RIBC will continue to be the primary supplier of blood and blood products to the hospitals in Rhode Island and throughout Southern New England. Smith adds, "RIBC's donors, blood drive sponsors, and hospital customers will continue to receive the same high quality services and blood products they have come to expect from us. The long-term goal is to maximize the operational synergies between our two organizations."
The affiliation will also serve to share best practices and efficiencies in all service lines from blood management and utilization to cellular collection for therapeutics. For example, both RIBC and NYBC provide direct patient care through their therapeutics programs, which utilize donated blood to remove abnormal blood components or cells from patients while returning healthy cells.
Under the terms of the agreement, RIBC continues to operate under its own name, FDA licensure, and remains a not-for-profit 501(c)3 organization, as is NYBC.